Myeloid neoplasia in children treated for solid tumours

C. H. Pui, E. Thompson, J. Wilimas, L. C. Bowman, W. M. Crist, C. B. Pratt, C. H. Pui, S. C. Raimondi, D. R. Head, L. E. Kun, M. L. Hancock, C. H. Pui, E. Thompson, J. Wilimas, L. C. Bowman, W. M. Crist, C. B. Pratt

Research output: Contribution to journalArticlepeer-review

99 Scopus citations


Therapy-related myeloid neoplasia developed 14 to 189 months after diagnosis of the primary malignancy in 12 out of 3365 children treated for malignant solid tumours; 6 of the 12 were in their first complete remission. The 10-year cumulative incidence of myeloid neoplasia was 1·3% (95% Cl 0·5-3·6) for the 447 patients with Hodgkin's disease, 1·3% (0·4-4·3) for the 420 with non-Hodgkin lymphoma, and 1·2% (0·3-5·2) for the 440 with neuroblastoma. This complication appeared in 1 of 180 children with brain tumours and in none of the 1878 with other malignancies. Risk of therapy-related myeloid neoplasia in patients with Hodgkin's disease was associated with recurrence of the primary malignancy, a combination of radiotherapy and chemotherapy with alkylating agents, and age ≥12 years at diagnosis of Hodgkin's disease. Of the 8 patients who underwent chromosomal analysis of neoplastic myeloid cells, 2 showed complete loss of chromosome 7 and 4 showed t(9;11) or t(8;21) with or without del(16)(q22). The 2 patients who had received an epipodophyllotoxin had an 11q23 abnormality. The risk of therapy-related myeloid neoplasia is low in children with malignant solid tumours.

Original languageEnglish (US)
Pages (from-to)417-421
Number of pages5
JournalThe Lancet
Issue number8712
StatePublished - Aug 18 1990

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Myeloid neoplasia in children treated for solid tumours'. Together they form a unique fingerprint.

Cite this